Acthar Gel in African Americans versus Non-African Americans with Symptomatic Sarcoidosis: Physician Assessment of Patient Medical Records
Jas Bindra,Ishveen Chopra,Kyle Hayes,John Niewoehner,Mary Panaccio,George Wan
DOI: https://doi.org/10.2147/tcrm.s438174
2024-02-10
Therapeutics and Clinical Risk Management
Abstract:Jas Bindra, 1 Ishveen Chopra, 2 Kyle Hayes, 3 John Niewoehner, 3 Mary Prince Panaccio, 3 George J Wan 3 1 Falcon Research Group, North Potomac, MD, USA; 2 Manticore Consultancy, Bethesda, MD, USA; 3 Mallinckrodt Pharmaceuticals, Bridgewater, NJ, USA Correspondence: George J Wan, Mallinckrodt Pharmaceuticals, 440 Route 22 East, Bridgewater, NJ, USA, Email Introduction: Sarcoidosis is common among African Americans in the United States. Acthar ® Gel is a viable option for the treatment of advanced symptomatic sarcoidosis. This study examined patient characteristics, Acthar Gel utilization, co-medication use, and treatment response based on physicians' assessments among African Americans versus non-African Americans with advanced symptomatic sarcoidosis. Methods: Data from the medical charts of patients were used. During data collection, patients had either completed ≥ 1 course or received treatment with Acthar Gel for ≥ 6 months. Results: This study comprised 168 African Americans and 104 non-African Americans. On average, the time since the first diagnosis of sarcoidosis was slightly longer among African Americans than non-African Americans (5.2 versus 4.3 years). Skin, heart, eyes, and joints were the most common extrapulmonary sites involved among both race groups. Shortness of breath, fatigue, bone and joint pain, and wheezing/coughing were the most frequent symptoms among both race groups. A higher proportion of African Americans versus non-African Americans were first-time Acthar Gel users and had not completed treatment during data collection. Patients in both race groups with higher starting doses of Acthar Gel therapy had a shorter treatment duration and vice-versa. A significantly lower proportion of patients among both race groups were on any co-medication after Acthar Gel initiation (p< 0.0001). Further, a higher proportion of African Americans versus non-African Americans had a reduction in any co-medication use after Acthar Gel initiation. The mean daily dose of prednisone decreased among African Americans (18.5 to 10.1 mg) and non-African Americans (17.6 to 10.0 mg) after Acthar Gel initiation. Improvement in patient health status and overall symptoms was similar for both race groups. Conclusion: Findings suggest that Acthar Gel improves health outcomes for patients with sarcoidosis, which could help to alleviate health disparities among African Americans, who are disproportionately affected by this disease. Keywords: Acthar ® Gel, African Americans, medical chart review, sarcoidosis, treatment utilization, treatment response Sarcoidosis is an inflammatory granulomatous condition with unknown etiology that affects multiple organs. 1–4 Patients experience a broad spectrum of clinical manifestations of varying severity that impair both mental and physical functioning. 5 The disability from sarcoidosis can result in a considerable direct and indirect economic burden on patients. 5 More than 25,000 patients are diagnosed with sarcoidosis each year in the United States (US). 6 Sarcoidosis-related hospitalization rates in the US have increased by about 26% from 2005 to 2014. 7 Advanced sarcoidosis results in considerable morbidity and some mortality; one or more types of advanced disease are reported in about 25% of patients with sarcoidosis that requires close monitoring and multiple treatments. 8 The African American population in the US is more frequently affected; 4 to 17 times more likely to develop sarcoidosis as compared to Caucasians. 9 Further, these patients may experience a worse sarcoidosis prognosis, lower health-related quality-of-life (QoL), and higher hospitalization and mortality rates. 5,10–12 In general, African Americans are underrepresented in research on rheumatic-related diseases, despite experiencing the disproportionate effect of these disorders. 13,14 Therefore, it is important to close the gaps in healthcare disparities through the provision of effective interventions to underserved populations with sarcoidosis. Previous studies suggest that Acthar ® Gel (repository corticotropin injection; Mallinckrodt Pharmaceuticals) is a viable option for the treatment of advanced symptomatic sarcoidosis. 15–17 Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogues and other pituitary peptides that interacts with all five melanocortin receptors. Its therapeutic effects in sarcoidosis may thus be attributed to the activation of several potential anti-inflammatory pathways through both glucocorticoid-dependent and independent mechanisms. 18</su -Abstract Truncated-
health care sciences & services